A Case-Based Approach to Improve Alzheimer's Diagnosis and Treatment, Hilton New Orleans Riverside, New Orleans, La - April 22, 2004

Course Abstracts/Summary

This interactive series of free CME courses is based on presentations recently given at cutting-edge national seminars and meetings by experts in the fields of Alzheimer's disease and dementia in general. These exciting new courses include multimedia slides, audio, video, and animations and provide up-to-date information on the evaluation, diagnosis, and treatment of Alzheimer's disease. This course is accredited for 1.5 hours of AMA PRA category 1 credit.

Accreditation

This course is jointly sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ), New Jersey Medical School, Department of Internal Medicine, UMDNJ-Center for Continuing and Outreach Education and eMedicine. UMDNJ Center for Continuing and Outreach Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UMDNJ-Center for Continuing and Outreach Education designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity was prepared in accordance with the ACCME Essentials.

Acknowledgement

This activity is supported by an unrestricted educational grant from Forest Laboratories, Inc.

Course Objectives

After participating in this program, the attendees will be better able to:

• Recognize and identify the symptoms and warning signs of AD and perform practical diagnostic and assessment procedures for the early diagnosis of AD
• Formulate optimal care management plans for patients with AD while balancing the need for treatment efficacy and patient safety
• Critically evaluate emerging therapies for patients at any stage of AD and use different treatment strategies that benefit the patient

Faculty Disclosures

In accordance with the disclosure policies of UMDNJ, and to conform with Accreditation Council for Continuing Medical Education (ACCME) and US Food and Drug Administration (FDA) guidelines, all program faculty members are required to disclose to activity participants (1) the existence of any financial interests or other relationships with manufacturers of any commercial products/devices, providers of commercial services that relate to the content of their presentation/material, or commercial contributors to this activity that could be perceived as a real or apparent conflict of interest. Faculty members must also reveal whether any mentioned commercial product/device is unlabeled for use or is being investigated for use but is not yet approved.

Eric G. Tangalos, MD, FACP, AGSF, CMD, is a consultant for Abbott Laboratories, Janssen Pharmaceutica, and Eli Lilly and Company.

George T. Grossberg, MD, receives grant/research support from Forest Laboratories, Novartis Pharmaceuticals, Janssen Pharmaceutica, GlaxoSmithKline, Organon, Wyeth, Boehringer Ingelheim, Eli Lilly and Company, Abbott Laboratories, and Eunoe, Inc. He is a consultant for Forest Laboratories, Novartis Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly and Company, AstraZeneca Pharmaceuticals LP, and Sanofi-Synthelabo.

Elaine R. Peskind, MD, is a consultant for Novartis Pharmaceuticals and receives grant/research support from Forest Laboratories and Janssen Pharmaceutica. She has been with speakers bureaus from Forest Laboratories, Pfizer, Janssen Pharmaceutica, and Novartis Pharmaceuticals.

Keerti Sharma, MD, has no significant financial relationships to disclose.

Instructions to Participants

Course participants must read the learning objectives, view the slide/audio presentations, and successfully complete the post-test in order to receive CME credit. Full instructions are available on the course navigation page.

Disclaimer

The views expressed in this activity are those of the faculty, and it should not be inferred or assumed that they are expressing the views of Forest Laboratories, Inc, any other pharmaceutical manufacturer, UMDNJ, or eMedicine, Inc.

The drug selection and dosage information presented in this activity are believed to be accurate. However, before prescribing any medication, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects. This is particularly important when a drug is new or infrequently prescribed.

Click here to view minimum system requirements.